文献速递脑血管病

急性缺血性卒中延长时间窗静脉溶栓:更新系统综述与荟萃分析

IV Thrombolysis in the Extended Time Window for Acute Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
PubMed 文献 · Neurology · 2026-07-23

该系统综述与荟萃分析纳入13项研究,比较最后已知正常时间超过4.5小时的急性缺血性卒中患者接受静脉溶栓联合最佳药物治疗与单纯最佳药物治疗的疗效与安全性。结果显示静脉溶栓显著改善90天极佳功能结局(RR 1.23;95%CI 1.15-1.33;NNT=13),但症状性颅内出血风险增加(RR 2.11;95%CI 1.36-3.28;NNH=75),两组全因死亡率相似。

要点

  • 延长时间窗静脉溶栓可改善90天功能结局,NNT=13。
  • 症状性颅内出血风险升高(RR 2.11),需权衡获益与出血风险。
  • 全因死亡率与任何颅内出血率两组相似,支持在筛选患者中使用。

核心结论

  • 最后已知正常超过4.5小时的急性缺血性卒中患者接受静脉溶栓与功能结局改善相关,且未增加死亡率,尽管症状性颅内出血率更高。

研究设计与样本

  • 系统检索MEDLINE、Scopus和ClinicalTrials.gov,纳入比较静脉溶栓联合最佳药物治疗与单纯最佳药物治疗的随机对照试验及个体患者数据荟萃分析。
  • 共纳入13项研究,静脉溶栓组2456例(平均年龄68.2岁;女性37%;基线NIHSS平均11.5),对照组2411例(平均年龄68.6岁;女性38%;基线NIHSS平均11.0)。
  • 对主要结局进行试验序贯分析以评估累积证据的稳健性。

主要发现

  • 静脉溶栓显著改善90天极佳功能结局(mRS 0-1)(RR 1.23;95%CI 1.15-1.33;I2=0%;NNT=13)。
  • 静脉溶栓改善良好功能结局(mRS 0-2)(RR 1.15;95%CI 1.05-1.25;I2=59%)并减少残疾(common OR 1.26;95%CI 1.13-1.39;I2=0%)。
  • 静脉溶栓与症状性颅内出血风险增加相关(RR 2.11;95%CI 1.36-3.28;I2=0%;NNH=75)。
  • 任何颅内出血和90天全因死亡率两组间相似。
  • 各预设亚组(溶栓药物、治疗时间窗、影像筛选策略、血管分布区域、血管内治疗)间未见显著差异。

关键数值与推荐

  • 主要疗效结局为90天极佳功能结局(mRS 0-1);次要疗效结局为良好功能结局(mRS 0-2)和残疾减少(mRS≥1分移位)。
  • 主要安全结局为症状性颅内出血;次要安全结局为任何颅内出血和90天全因死亡率。
  • 试验序贯分析确认主要结局的累积证据跨越疗效边界,支持稳健的治疗效应。

临床怎么用

  • 对最后已知正常超过4.5小时的急性缺血性卒中患者,可在筛选后考虑静脉溶栓以改善功能结局。
  • 决策时需权衡功能获益与症状性颅内出血风险增加(NNH=75)。
  • 治疗选择可参考影像筛选策略及是否联合血管内治疗等亚组因素。

局限性

  • 检索仅限MEDLINE、Scopus和ClinicalTrials.gov,可能遗漏其他数据库文献。
  • 良好功能结局分析存在中度异质性(I2=59%)。
  • 纳入研究为随机对照试验及个体患者数据荟萃分析,未报告其他研究设计证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: IV thrombolysis (IVT) is the standard treatment for acute ischemic stroke (AIS) within 4.5 hours of symptom onset, yet many patients present beyond this window. Recent randomized-controlled clinical trials (RCTs) and updated guidelines suggest potential benefit of IVT in selected patients treated in the extended time window, but the overall evidence remains evolving. We aimed to evaluate the efficacy and safety of IVT beyond 4.5 hours from last known well. METHODS: We systematically searched MEDLINE, Scopus, and ClinicalTrials.gov for RCTs and individual patient data meta-analyses of RCTs comparing IVT plus best medical therapy (BMT) with BMT alone in patients with AIS presenting more than 4.5 hours after last known well. The primary efficacy outcome was excellent functional outcome at 90 days (modified Rankin Scale [mRS] score 0-1). Secondary efficacy outcomes included good functional outcome (mRS 0-2) and reduced disability (≥1-point shift across the mRS). The primary safety outcome was symptomatic intracranial hemorrhage (sICH); secondary safety outcomes were any ICH and all-cause mortality at 90 days. Prespecified subgroup analyses were performed according to thrombolytic agent, treatment window, imaging selection strategy, vascular territory, and administration of endovascular treatment. Trial sequential analysis was conducted for the primary outcome to evaluate the robustness of the cumulative evidence. RESULTS: Thirteen studies were included, comprising 2,456 patients in the IVT group (mean age = 68.2 years; 37% female, mean baseline NIH Stroke Scale [NIHSS] score = 11.5) and 2,411 patients in the control group (mean age = 68.6 years; 38% female, mean baseline NIHSS score = 11.0). IVT significantly improved excellent functional outcome (risk ratio [RR] 1.23; 95% CI 1.15-1.33; I2 = 0%; NNT = 13), good functional outcome (RR 1.15; 95% CI 1.05-1.25; I2 = 59%), and reduced disability (common odds ratio 1.26; 95% CI 1.13-1.39; I2 = 0%). IVT was associated with increased risk of sICH (RR 2.11; 95% CI 1.36-3.28; I2 = 0%; NNH = 75). The rates of any ICH and all-cause mortality were similar between the 2 groups. No significant subgroup differences were documented across different subgroups. Trial sequential analysis confirmed that the cumulative evidence for the primary outcome crossed the efficacy boundary, supporting a robust treatment effect. DISCUSSION: IVT in the extended time window was associated with improved functional outcomes without increased mortality, supporting its use in selected patients despite a higher rate of sICH. TRIAL REGISTRATION INFORMATION: The prespecified protocol of the present systematic review and meta-analysis has been registered in the International Prospective Register of Ongoing Systematic Reviews (registration ID: CRD420261330511).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Palaiodimou L, Papageorgiou NM, Romoli M, et al. IV Thrombolysis in the Extended Time Window for Acute Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. Neurology. 2026. PMID: 42492020. doi:10.1212/WNL.0000000000218294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。